Rho Experts Provide Gene Therapy Development Tips

CHAPEL HILL, NC, UNITED STATES - Oct 16, 2018 - WHAT:  Rho, a full-service contract research organization (CRO), will highlight tips for developing gene therapy products in a new free webinar, “Development Advice for Gene Therapy Products.” The webinar will take place on Wednesday, October 24 from 1-2 p.m. EST.

Rho experts David Shoemaker, PhD, senior vice president, R&D; Jamison Chang, MD, medical officer; Dana Minnick, PhD, senior research scientist; and Scott Burian, PhD, senior research scientist will present the webinar. Attendees can expect to learn more about the development of new gene therapy products from a variety of perspectives, including regulatory strategy, clinical development, pharmacology/toxicology considerations and CMC development. The webinar will also cover the FDA’s latest statement on gene therapy and the six new or revised guidance documents.

WHO: David Shoemaker, PhD, senior vice president, R&D, has more than 25 years of experience in research and pharmaceutical development, and has been involved with products at all stages of the development process.

Jamison Chang, MD, medical officer, is a board-certified internist with over 15 years of clinical experience with a broad range of disease entities in both the ambulatory and hospital settings. After completing his residency and chief residency at UNC Chapel Hill, he obtained additional training in nephrology as well as a master’s degree in clinical research (MS-CR). These experiences allow Dr. Chang to meld clinical pragmatism with scientific rigor to help plan and conduct high quality clinical trials.

Dana Minnick, PhD, DABT, RAC, senior research scientist, is a toxicologist and regulatory affairs professional with over 19 years of experience in leading and supporting drug and biologics programs through the development lifecycle.

Scott Burian, PhD, senior research scientist, is a broadly-experienced regulatory affairs professional with more than 15 years of experience contributing to the development of small molecule, biologic and nanoparticle-based gene therapy products.

WHEN: October 24, 2018
              1-2 p.m. EST

WHERE:  Register to attend this free webinar at this link.

DETAILS:  For media inquiries, please contact Jordan Lockhart at Largemouth Communications, 919-459-6461, jordan@largemouthpr.com.   

ABOUT: Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.

###